PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile | PTCT Stock NewsStockTitan·2 days ago, 11:00 PMPTCT-0.53%
PTC Therapeutics Director Michael Schmertzler sells 24,000 shares for $1.73 millionPUBT·Aug 21 at 04:20 PMPTCT-0.53%
PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding disposes of 2,813 common shares worth $204,863.91PUBT·Aug 19 at 04:20 PMPTCT-0.53%
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction DealMarket Beat·Aug 16 at 10:01 AMPTCT-0.53%
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'benzinga_article·Aug 13 at 11:28 AMPTCT-0.53%
Sangamo selects winning bids in Chapter 11 asset auction for USD 163.55 million cash at closePUBT·Aug 12 at 03:28 PMSGMOQ+0.40%LLY-3.75%
PTC Therapeutics to buy Sangamo’s ST-920 Fabry gene therapy program for $111 million upfrontPUBT·Aug 12 at 03:02 PMPTCT-0.53%
Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board AppointmentSimplywall·Aug 12 at 02:36 AMPTCT-0.53%
Top 3 Health Care Stocks You'll Regret Missing This Quarterbenzinga_article·Aug 4 at 05:04 AMPTCT-0.53%SUPN-1.26%
Empowered Funds LLC Sells 192,506 Shares of PTC Therapeutics, Inc. $PTCTMarket Beat·Aug 3 at 02:37 AMPTCT-0.53%STT+0.39%
Sei Investments Co. Raises Stake in PTC Therapeutics, Inc. $PTCTMarket Beat·Aug 2 at 03:56 AMPTCT-0.53%
PTC Therapeutics (NASDAQ:PTCT) Upgraded to "Strong-Buy" at Wall Street ZenMarket Beat·Aug 1 at 12:48 AMPTCT-0.53%
PTC Therapeutics director Hege Elisabeth Sollie-Zetlmayer files initial beneficial ownership statementPUBT·Jul 30 at 08:00 PMPTCT-0.53%
